Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Marinus Pharma CS (NQ: MRNS ) 1.450 +0.020 (+1.40%) Streaming Delayed Price Updated: 11:35 AM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 157,242 Open 1.430 Bid (Size) 1.440 (16) Ask (Size) 1.450 (24) Prev. Close 1.430 Today's Range 1.425 - 1.450 52wk Range 1.110 - 11.26 Shares Outstanding 54,933,774 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS July 20, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm July 18, 2024 From Bragar Eagel & Squire Via GlobeNewswire Performance YTD -86.06% -86.06% 1 Month +9.02% +9.02% 3 Month -1.69% -1.69% 6 Month -85.67% -85.67% 1 Year -85.29% -85.29% More News Read More SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus July 18, 2024 From Faruqi & Faruqi LLP Via GlobeNewswire Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder July 18, 2024 From Marinus Pharmaceuticals Via Business Wire ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS July 17, 2024 From The Rosen Law Firm PA Via GlobeNewswire MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 17, 2024 From Schall Law Via GlobeNewswire MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline July 15, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm July 14, 2024 From Bragar Eagel & Squire Via GlobeNewswire ROSEN, A LEADING AND RANKED FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS July 13, 2024 From The Rosen Law Firm PA Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm July 10, 2024 From Bragar Eagel & Squire Via GlobeNewswire ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS July 10, 2024 From The Rosen Law Firm PA Via GlobeNewswire MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 10, 2024 From Schall Law Via GlobeNewswire MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline July 08, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm July 06, 2024 From Bragar Eagel & Squire Via GlobeNewswire MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm July 03, 2024 From Schall Law Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Lamb Weston, and Teradata and Encourages Investors to Contact the Firm July 02, 2024 From Bragar Eagel & Squire Via GlobeNewswire ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS July 01, 2024 From The Rosen Law Firm PA Via GlobeNewswire MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline July 01, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Lamb Weston, and Teradata and Encourages Investors to Contact the Firm June 28, 2024 From Bragar Eagel & Squire Via GlobeNewswire ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS June 28, 2024 From The Rosen Law Firm PA Via GlobeNewswire MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm June 26, 2024 From Schall Law Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Lamb Weston, and Teradata and Encourages Investors to Contact the Firm June 24, 2024 From Bragar Eagel & Squire Via GlobeNewswire MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline June 24, 2024 From Bernstein Liebhard LLP Via GlobeNewswire Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Lamb Weston, and Teradata and Encourages Investors to Contact the Firm June 20, 2024 From Bragar Eagel & Squire Via GlobeNewswire Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS) June 20, 2024 From Glancy Prongay & Murray LLP Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.